Motohiro Yamamori[Author] - Search Results

Year	Number of Results
2003	1
2004	1
2007	3
2008	8
2009	4
2010	2
2011	7
2012	5
2013	1
2014	2
2016	2
2017	2
2018	1
2021	2
2022	2
2024	0

1

Pharmacogenetics of intestinal absorption.

Nakamura T, Yamamori M, Sakaeda T. Nakamura T, et al. Among authors: yamamori m. Curr Drug Deliv. 2008 Jul;5(3):153-69. doi: 10.2174/156720108784911749. Curr Drug Deliv. 2008. PMID: 18673259 Review.

2

Pharmacokinetics and pharmacogenomics in esophageal cancer chemoradiotherapy.

Sakaeda T, Yamamori M, Kuwahara A, Nishiguchi K. Sakaeda T, et al. Among authors: yamamori m. Adv Drug Deliv Rev. 2009 May 20;61(5):388-401. doi: 10.1016/j.addr.2008.10.005. Epub 2008 Dec 24. Adv Drug Deliv Rev. 2009. PMID: 19135108 Review.

3

Mycophenolate mofetil: fully utilizing its benefits for GvHD prophylaxis.

Minagawa K, Yamamori M, Katayama Y, Matsui T. Minagawa K, et al. Among authors: yamamori m. Int J Hematol. 2012 Jul;96(1):10-25. doi: 10.1007/s12185-012-1086-x. Epub 2012 May 17. Int J Hematol. 2012. PMID: 22592321 Review.

4

Troglitazone-Induced Autophagic Cytotoxicity in Lung Adenocarcinoma Cell Lines.

Tsujiya Y, Hasegawa A, Yamamori M, Okamura N. Tsujiya Y, et al. Among authors: yamamori m. Biol Pharm Bull. 2022;45(3):276-283. doi: 10.1248/bpb.b21-00785. Biol Pharm Bull. 2022. PMID: 35228393 Free article.

5

Telmisartan Exerts Cytotoxicity in Scirrhous Gastric Cancer Cells by Inducing G₀/G₁ Cell Cycle Arrest.

Tsujiya Y, Yamamori M, Hasegawa AI, Yamamoto Y, Yashiro M, Okamura N. Tsujiya Y, et al. Among authors: yamamori m. Anticancer Res. 2021 Nov;41(11):5461-5468. doi: 10.21873/anticanres.15358. Anticancer Res. 2021. PMID: 34732415

6

Telmisartan-Induced Cytotoxicity via G₂/M Phase Arrest in Renal Cell Carcinoma Cell Lines.

Tsujiya Y, Hasegawa A, Yamamori M, Okamura N. Tsujiya Y, et al. Among authors: yamamori m. Biol Pharm Bull. 2021;44(12):1878-1885. doi: 10.1248/bpb.b21-00654. Biol Pharm Bull. 2021. PMID: 34853271 Free article.

7

In vitro and in vivo cytotoxicity of troglitazone in pancreatic cancer.

Fujita M, Hasegawa A, Yamamori M, Okamura N. Fujita M, et al. Among authors: yamamori m. J Exp Clin Cancer Res. 2017 Jul 3;36(1):91. doi: 10.1186/s13046-017-0557-6. J Exp Clin Cancer Res. 2017. PMID: 28673319 Free PMC article.

8

[Recent advances in PK-PD theory].

Sakaeda T, Kadoyama K, Yamamori M. Sakaeda T, et al. Among authors: yamamori m. Jpn J Antibiot. 2009 Dec;62(6):483-91. Jpn J Antibiot. 2009. PMID: 20545083 Review. Japanese. No abstract available.

9

In vivo evaluation of pharmacokinetic drug-drug interactions between fluorinated pyrimidine anticancer drugs, 5-fluorouracil and capecitabin, and an anticoagulant, warfarin.

Hasegawa A, Tsujiya Y, Ueda A, Yamamori M, Okamura N. Hasegawa A, et al. Among authors: yamamori m. Xenobiotica. 2022 Jun;52(6):608-612. doi: 10.1080/00498254.2022.2118643. Epub 2022 Sep 1. Xenobiotica. 2022. PMID: 36039774

10

Pharmacokinetics of intravenous mycophenolate mofetil in allogeneic hematopoietic stem cell-transplanted Japanese patients.

Kurata K, Yakushijin K, Okamura A, Yamamori M, Ichikawa H, Sakai R, Mizutani Y, Kakiuchi S, Miyata Y, Kitao A, Kawamoto S, Matsuoka H, Murayama T, Minami H. Kurata K, et al. Among authors: yamamori m. Cancer Chemother Pharmacol. 2018 May;81(5):839-846. doi: 10.1007/s00280-018-3550-7. Epub 2018 Mar 6. Cancer Chemother Pharmacol. 2018. PMID: 29511796

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

41 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

41 results

Results by year